Publications by authors named "J Fetting"
Purpose: Treatment-associated symptoms drive early discontinuation of adjuvant endocrine therapy (ET) for breast cancer. We hypothesized that symptom monitoring with electronic patient-reported outcomes (ePROs) during adjuvant ET will enhance symptom detection, symptom management, and persistence.
Methods: Eligible patients were initiating ET for stage 0-III breast cancer.
Introduction: Critical regulatory genes are functionally silenced by DNA hypermethylation in breast cancer and premalignant lesions. The objective of this study was to examine whether DNA methylation assessed in random fine needle aspirates (rFNA) can be used to inform breast cancer risk.
Methods: In 20 women with invasive breast cancer scheduled for surgery at Johns Hopkins Hospital, cumulative methylation status was assessed in a comprehensive manner.
Article Synopsis
- Many patients stop endocrine therapy for breast cancer due to side effects, making it tough to identify at-risk individuals.
- Research established the minimal important difference (MID), which highlights clinically significant changes in patient-reported outcomes (PROs).
- In a study of 321 women undergoing endocrine therapy, a correlation was found between worsening PRO scores and the likelihood of discontinuation, particularly linked to endocrine symptoms and sleep disturbances.*
Background: Poly-ADP ribose polymerase (PARP) inhibitors (PARPi) are active in patients with germline BRCA1/2 (gBRCA1/2)-mutated breast cancer, accounting for 5% to 10% of all breast cancers. Another 5% to 10% harbor somatic BRCA1/2 (sBRCA1/2) mutations or mutations in non-BRCA1/2, homologous recombination repair (HRR) genes but until recently, there were no data for the use of PARPi in these patients. This study examines the use of olaparib in patients with metastatic breast cancer harboring sBRCA1/2 or germline or somatic non-BRCA1/2, HRR mutations and demonstrates potential activity of PARPi in this setting.
View Article and Find Full Text PDFBackground: Forkhead transcription factors control cell growth in multiple cancer types. Foxd1 is essential for kidney development and mitochondrial metabolism, but its significance in renal cell carcinoma (ccRCC) has not been reported.
Methods: Transcriptome data from the TCGA database was used to correlate FOXD1 expression with patient survival.